New Head To Head Study Proves Non-inferiority Of Levitra(R) (vardenafil HCI) In Comparison To Viagra(R) (sildenafil) For Erectile Dysfunction

About Takeda Pharmaceutical Takeda Pharmaceutical, sited in Osaka, Japan, is a research-based intercontinental ensemble with its halcyon days focus by the haunch of pharmaceuticals. As the largest pharmaceutical company in Japan and one of the global leaders of the industry, Takeda is committed to striving toward improved stamina for individuals and progress in tablets by mushrooming superb pharmaceutical products. Additional numbers in the order of Takeda is available through its corporate website, Takeda PharmaceuticalTakeda Pharmaceutical

A sum of 1057 men be conscript to the study. 38.9% of men expressed an overall preference in support of Levitra carry out Viagra (34.5%) and 26.6% of patients seize no treatment preference. As this gap found be not statistically indicative, this end result confirm the non-inferiority of vardenafil. However vardenafil achieve nominal statistical excellence to sildenafil for several repetitively nearly new efficacy measures: Levitra achieved a slice into above feedback for men respond to the Sexual Encounter Profile examine 2 and 31 ; 83.9% of men taking Levitra respond confidently to SEP2 (p=0.0389) compared with 82.2% for Viagra and 74% of men story a functional response to Levitra for the question SEP3 (p=0.0038) antagonistic 72% for Viagra.

The CONFIRMED study minimize inequity see in other comparative trials with consciously invent an unbiased methodology that incorporated 13 definite criterion. Trial grades that be more whatsoever to be normal by the medical metropolitan are routinely randomised (patients are nominated changeably to be given one treatment or the other), double-blind (neither the investigator nor patient know which treatment the patient is taking until the finale of the study), cross-over design (each patient try one treatment and subsequent the other). This trial additionally used conflicting linctus dose, had a randomised treatment progression, used a lacklustre go-ahead contour, and assess preference after respectively treatment length and, importantly, fulfil not eliminate erstwhile non-responders or just enclose trusting patients (patients who had never used an ED treatment before).